Citations

Showing 10 of 108162 citations.

Stanniocalcin-1 Reduced Intraocular Pressure in Two Models of Ocular Hypertension
Roddy, Gavin W. , Chowdhury, Uttio Roy, Monson, Kjersten J., Fautsch, Michael P.

Mayo Clinic

Current Eye Research | March 24, 2021 | Volume: 46 | Issue: 10 | Pages: 1525-1530

10.1080/02713683.2021.1899246 | PMID 33757401 Get It

High-grade Transformation/Dedifferentiation in Salivary Gland Carcinomas: Occurrence Across Subtypes and Clinical Significance
Skálová, Alena , Simpson, Roderick H.W., Poorten, Vincent Vander , Willems, Stefan M. , Olsen, Kerry D., Ferlito, Alfio , Vander Poorten, Vincent , Leivo, Ilmo V.V. , Hellquist, Henrik B. , Agaimy, Abbas , Stenman, Göran , Bishop, Justin A. , Franchi, Alessandro , Hernandez‐Prera, Juan C. , Slouka, David

Mayo Clinic

Advances in Anatomic Pathology | March 24, 2021 | Volume: 28 | Issue: 3 | Pages: 107-118

10.1097/pap.0000000000000298 | PMID 33825717 Get It

High-grade transformation (HGT) or dedifferentiation has been described in a variety of salivary gland carcinomas, including acinic cell carcinoma, secretory carcinoma, adenoid cystic carcinoma, epithelial-myoepithelial carcinoma, polymorphous adenocarcinoma, low-grade mucoepidermoid carcinoma, and hyalinizing clear cell carcinoma. High-grade (HG) transformed tumors are composed of a conventional low-grade component characterized by specific microscopic and immunohistochemical features for the given entity, intermingled with or juxtaposed to areas of HG morphology. This is usually either poorly differentiated adenocarcinoma, carcinoma not otherwise specified, or undifferentiated carcinoma, in which the original line of differentiation is lost. The HG component is composed of solid nests of anaplastic cells with large vesicular pleomorphic nuclei, prominent nucleoli, and abundant cytoplasm. Frequent mitoses and extensive necrosis may be present. The Ki-67 labeling index is consistently higher in the HG component. The molecular genetic mechanisms responsible for HGT of salivary gland carcinomas are largely unknown, though p53 inactivation and human epidermal growth factor receptor 2 overexpression and/or gene amplification have been demonstrated in the HG component in a few examples, the frequency varies for each histologic type. Salivary gland carcinomas with HGT are more aggressive than conventional carcinomas, with a higher local recurrence rate and a poorer prognosis. They have a high propensity for cervical lymph node metastasis suggesting a need for a wider resection and neck dissection. HGT of salivary gland carcinoma can occur either at initial presentation or less commonly at the time of recurrence, sometimes following postoperative radiotherapy. The potential for HGT in almost any type of salivary gland carcinoma warrants a thorough sampling of all salivary gland malignancies to prevent oversight of a HG component.
Improving Outcomes in Cardiovascular Diseases: A Review on Vorapaxar
Mohananey, Akanksha, Sharma, Sharan Prakash , Singh, Amteshwar , Kondur, Ashok , Singh, Amteshwar , Chaudhary, Rahul , Sharma, Sharan Prakash , Singh, Sahib T

Mayo Clinic

Cardiology in Review | March 24, 2021 | Volume: 30 | Issue: 5 | Pages: 241-246

10.1097/crd.0000000000000390 | PMID 33758122 Get It

Antiplatelet agents are the standard of practice in the management of atherosclerosis and acute coronary syndrome. In contrast to the available antiplatelet agents, vorapaxar represents a novel mechanism of action. It is an antagonist of the platelet protease-activated receptor-1 and inhibits thrombin-induced and thrombin receptor agonist peptide-induced platelet aggregation. The Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-Thrombolysis in Myocardial Infarction 50 (TRA 2°P-TIMI 50) trial led to the approval of vorapaxar by the Food and Drug Administration and European Medicines Agency for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or peripheral arterial disease. TRA 2°P-TIMI 50 trial showed that the use of vorapaxar (2.5 mg once/daily) in addition to standard dual antiplatelet therapy with aspirin and a P2Y12 receptor inhibitor was effective in the secondary prevention of recurrent thrombotic events among patients with previous atherothrombosis, particularly in patients with prior MI; at the expense of an increase in major bleeding. Another recently published Vorapaxar Therapy in Patients With Prior Myocardial Infarction Treated With Newer Generation P2Y12 Receptor Inhibitors Prasugrel and Ticagrelor (VORA-PRATIC) study showed that among post-MI patients treated with potent P2Y12 inhibitors (prasugrel or ticagrelor), vorapaxar reduced platelet-driven global thrombogenicity, an effect that persisted, albeit attenuated, in the absence of aspirin. The current review summarizes an up-to-date literature on pharmacokinetics, pharmacodynamics, and clinical efficacy of vorapaxar and proposes future directions of research.
The Extravascular Implantable Cardioverter-Defibrillator: The Pivotal Study Plan
Crozier, Ian , O’Donnell, David , Murgatroyd, Francis , Manlucu, Jaimie , Birgersdotter‐Green, Ulrika , Leclercq, Christophe , Thompson, Amy , Sawchuk, Robert A., Willey, Sarah, Wiggenhorn, Christopher, Friedman, Paul A. , Thompson, Amy E , Crozier, Ian , Boersma, Lucas V.A. , Knight, Bradley P. , Sawchuk, Robert

Mayo Clinic

No container title available | March 23, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.161655539.90718828/v1 Get It

Background: Transvenous implantable cardiac defibrillators (TV ICD) provide life-saving therapy for millions of patients worldwide. However, they are susceptible to several potential short- and long- term complications including cardiac perforation and pneumothorax, lead dislodgement, venous obstruction, and infection. The extravascular ICD (EV ICD) system’s novel design and substernal implant approach avoids the risks associated with TV ICDs while still providing pacing features and similar generator size to TV ICDs. Study Design: The EV ICD pivotal study is a prospective, multi-center, single-arm, non-randomized, pre-market clinical study designed to examine the safety and acute efficacy of the system. This study will enroll up to 400 patients with a Class I or IIa indication for implantation of an ICD. Implanted subjects will be followed up to approximately 3.5 years, depending on when the patient is enrolled. Objective: The clinical trial is designed to demonstrate safety and effectiveness of the EV ICD system in human use. The safety endpoint is freedom from major complications, while the efficacy endpoint is defibrillation success. Both endpoints will be assessed against prespecified criteria. Additionally, this study will evaluate antitachycardia pacing (ATP) performance, electrical performance, extracardiac pacing sensation, asystole pacing, appropriate and inappropriate shocks, as well as a summary of adverse events. Conclusion: The EV ICD pivotal study is designed to provide clear evidence addressing the safety and efficacy performance of the EV ICD System.
Honeycomb Epithelial Edema Associated With Rho Kinase Inhibition: A Case Series and Review of the Literature
Lyons, Lance J. , Wu, Kristi Y., Baratz, Keith H. , Sit, Arthur J. , Sit, Arthur J

Mayo Clinic

Cornea | March 23, 2021 | Volume: 41 | Issue: 2 | Pages: 243-248

10.1097/ico.0000000000002694 | PMID 35037906 Get It

Abstract: The Rho kinase inhibitor netarsudil is a recently approved therapeutic option for the management of increased intraocular pressure in the United States. Although phase 3 clinical trials noted corneal changes related to the medication—namely, nonvisually-significant corneal verticillata—descriptions of a unique form of cystic epithelial edema began to surface as netarsudil (and its sister drug ripasudil, approved in Japan) gained widespread use. This series adds 3 new cases and reviews the current literature on this unique side effect.
Membranous nephropathy: a single disease or a pattern of injury resulting from different diseases
Sethi, Sanjeev

Mayo Clinic

Clinical Kidney Journal | March 23, 2021 | Volume: 14 | Issue: 10 | Pages: 2166-2169

10.1093/ckj/sfab069 | PMID 34603694 Get It

Abstract Membranous nephropathy (MN) is defined as disease entity characterized by thickening of the glomerular basement membranes due to subepithelial (SE) deposition of immune complexes. It is typically classified into primary MN (70%) when there is no disease association, and secondary MN (30%) when there is an underlying disease association such as lupus, malignancy, infections or drugs. Phospholipase A2 receptor (PLA2R) and thrombospondin type-1 domain-containing 7A (THSD7A) are target antigens in 70% and 1–5% of primary MN, respectively. The antigens in the remaining MN were not known. Recently, multiple novel proteins/target antigens have been identified in MN. These include exostosin 1/2, neural epidermal growth-like 1 protein, semaphorin 3B, protocadherin 7 and neural cell adhesion molecule 1. Some of these antigens are present in the setting of primary MN, some in secondary MN and some in both, thus blurring the lines between primary and secondary MN. Preliminary studies show that each of the new antigen-associated MN has distinct clinical, kidney biopsy findings and outcome data. We propose that each new protein/antigen-associated MN is a specific disease that results in the common MN pattern of injury characterized by thickened glomerular basement membrane (GBM) with or without spikes or pinholes on light microscopy, granular immunoglobulin G with or without complement 3 on immunofluorescence microscopy and SE electron-dense deposits on electron microscopy. In other words, MN is truly only a pattern of injury resulting from specific diseases that cause deposition of SE immune deposits along the GBM. It is of paramount importance to ascertain the specific disease entity causing the MN pattern not only for precise diagnosis and management, but also for future studies on these newly described diseases.
The Aging Surgeon: Evidence and Experience
Asserson, Derek B. , Janis, Jeffrey E.

Mayo Clinic

Aesthetic Surgery Journal | March 23, 2021 | Volume: 42 | Issue: 1 | Pages: 121-127

10.1093/asj/sjab145 | PMID 33755726 Get It

Abstract Background With doctors in short supply and a strong demand for surgeon services in all areas of the United States, urban and rural, there are pressures to remain in active practice for longer. Even with an older workforce, there are currently no requirements for when a surgeon must retire in the United States. Objectives The aim of this article was to highlight the importance of the aging surgeon to the medical community and to provide an evidence-based overview of age-related cognitive and physical issues that develop during the later stages of a surgeon’s career. Methods A search of the PubMed/MEDLINE database was performed for the phrase “aging surgeon.” Inclusion criteria were applied to include only those articles related to surgeon age or retirement. Additional reports were handpicked from citations to substantiate claims with statistical evidence. Results The aging surgeon contributes extensive experience to patient care, but is also prone to age-related changes in cognition, vision, movement, and stress as it relates to new techniques, surgical performance, and safety measures. Studies show that although surgeons are capable of operating well into their senior years, there is the potential of decline. Nevertheless, there are proven recommendations on how to prepare an older surgeon for retirement. Conclusions Age-related trends in cognitive and physical decline must be counterbalanced with wisdom gained through decades of surgical experience.
New Decade, Old Debate: Blocking the Cytokine Pathways in Infection-Induced Cytokine Cascade
Rizvi, Mahrukh, Moraes, Alice Gallo de

Mayo Clinic

Critical Care Explorations | March 23, 2021 | Volume: 3 | Issue: 3 | Pages: e0364

10.1097/cce.0000000000000364 | PMID 33786440 Get It

Objectives: Our understanding of the immunopathogenesis of coronavirus disease 2019 is evolving; however, a “cytokine storm” has been implicated. Ongoing clinical trials are evaluating the value of anticytokine therapies to treat patients with coronavirus disease 2019. This review summarizes the existing literature evaluating the efficacy and safety of anticytokine therapy to tackle the dysregulated immune response to infectious pathogens, discusses potential reasons for failure, applicability to coronavirus disease 2019, and future direction. Data Sources: Medline, PubMed, ClinicalTrials.gov, and media reports. Study Selection: The studies were included by author consensus. Data Extraction: Data were selected for inclusion after reviewing each study by author consensus. Data Synthesis: “Cytokine storm” is a nonspecific term, encompassing systemic inflammatory response to infectious pathogens, autoimmune conditions, cancers, trauma, and various chemotherapies. Like bacterial sepsis, viral pathogens may fuel immunopathogenesis by inducing a dysregulated autoamplifying cytokine cascade, ultimately leading to organ injury. This narrative review discusses what we know of the immune milieu of coronavirus disease 2019 versus noncoronavirus disease 2019 sepsis and/or acute respiratory distress syndrome, summarizes the existing literature on cytokine inhibitors in patients with sepsis and/or acute respiratory distress syndrome, and discusses possible reasons for recurrent failure. In doing so, it aims to assist decisions regarding the use of anticytokine therapy in patients with coronavirus disease 2019, as many regions of the world confront the second wave of the pandemic. Conclusions: As ongoing clinical trials determine the efficacy and safety of anticytokine therapy in patients with coronavirus disease 2019, clinicians should uphold caution when incorporating it into treatment protocols, while maintaining focus on established evidence-based practices and the mantra of “less is more.”
Topical Amitriptyline-Ketamine for Treatment of Rectal, Genital, and Perineal Pain and Discomfort
Davis, Mark D. P., Davis, Mark D.P.

Mayo Clinic

Pain Physician | March 23, 2021 | Volume: 6;15 | Issue: 6;12 | Pages: 485-488

10.36076/ppj.2012/15/485 Get It

Background: Pain in the rectal, genital, and perineal area is a common condition treated by pain physicians. These chronic pain syndromes are therapeutically challenging because both interventional and drug therapies often are ineffective. Objectives: To determine if pelvic pain can be treated effectively with compounded topical amitriptyline-ketamine. Study Design: A retrospective review of medical records. Setting: A single academic medical center in the United States. Methods: We identified all patients treated with topical amitriptyline-ketamine from January 1, 2004, through November 28, 2011. Medical records were evaluated to determine the diagnosis for which the medication was prescribed. Treatment efficacy and any adverse effects were recorded. Results: Of the 1,068 patients who received amitriptyline-ketamine, 13 had the medication prescribed for genital, rectal, or perineal pain and had medication efficacy recorded. These patients were treated with a topical combination of amitriptyline 1-2% and ketamine 0.5%. Of these 13 patients, one (8%) had complete relief, 6 (46%) had substantial relief, 4 (31%) had some relief, and 2 (15%) had no response. One patient reported occasional irritation while using topical amitriptyline-ketamine with lidocaine; no other patients reported local or systemic adverse effects. Limitations: Retrospective review; lack of uniform system for pain grading; concurrent use of other medications. Conclusions: Topical amitriptyline-ketamine provided a high rate of pain relief with a low adverse-effect burden in patients with pelvic pain. This topical medication could offer an effective, noninvasive, nonopioid therapy for pain in the rectum, perineum, and genitals. Key words: Amitriptyline, rectal, compounded medication, genital, ketamine, pain, pelvic, perineal.
A distributionally robust optimization approach for coordinating clinical and surgical appointments
Berg, Bjorn P. , Huang, Yu-Li , Bansal, Ankit

Mayo Clinic

IISE Transactions | March 23, 2021 | Volume: 53 | Issue: 12 | Pages: 1311-1323

10.1080/24725854.2021.1906467 Get It